Siragy H M, Howell N L, Peach M J, Carey R M
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville 22908.
Am J Physiol. 1990 Mar;258(3 Pt 2):F522-9. doi: 10.1152/ajprenal.1990.258.3.F522.
We produced maximal or near-maximal acute intrarenal blockade of the renin-angiotensin system (RAS) by combining inhibitors. Intrarenal infusion of the renin inhibitor, ACRIP, the converting enzyme inhibitor, teprotide, and saralasin were administered individually or combined in random order. The inhibitors were infused for 20 min in doses that did not produce systemic effects in uninephrectomized conscious dogs in sodium balance at 10 meq/day. Significant increases in urine flow rate (UV; F = 97, P less than 0.0001), urinary sodium excretion (UNaV; F = 220, P less than 0.0001), glomerular filtration rate (GFR; F = 64, P less than 0.0001), and renal plasma flow (RPF; F = 108, P less than 0.0001) were observed with each blocker, whether alone or in combination except that ACRIP alone did not alter GFR or RPF. The increase in renal function was related to the number of blockers (3 greater than 2 greater than 1). With the three blockers combined UV increased approximately sixfold (from 0.5 +/- 0.06 to 2.9 +/- 0.03 ml/min), UNaV approximately 10-fold (from 3 +/- 0.4 to 34 +/- 2.8 mueq/min), GFR from 31 +/- 2 to 49 +/- 2 ml/min, RPF from 59 +/- 1 to 120 +/- 4 ml/min, and fractional excretion of sodium from 0.06 +/- 0.01 to 0.5 +/- 0.4% (all P less than 0.001). These changes did not occur where the inhibitors were infused systemically and the changes during intrarenal blocker administration were blocked completely with co-administration of angiotensin II intrarenally. The intrarenal RAS is a potent physiological regulator of renal function.(ABSTRACT TRUNCATED AT 250 WORDS)
我们通过联合使用抑制剂,对肾素-血管紧张素系统(RAS)进行了最大程度或接近最大程度的急性肾内阻断。在钠平衡为10 meq/天的情况下,对单侧肾切除的清醒犬,以随机顺序单独或联合给予肾素抑制剂ACRIP、转化酶抑制剂替普罗肽和沙拉新进行肾内输注。抑制剂以不产生全身效应的剂量输注20分钟。无论是单独使用还是联合使用,每种阻滞剂均观察到尿流率(UV;F = 97,P<0.0001)、尿钠排泄(UNaV;F = 220,P<0.0001)、肾小球滤过率(GFR;F = 64,P<0.0001)和肾血浆流量(RPF;F = 108,P<0.0001)显著增加,但单独使用ACRIP时未改变GFR或RPF。肾功能的增加与阻滞剂的数量有关(3>2>1)。三种阻滞剂联合使用时,UV增加约6倍(从0.5±0.06增至2.9±0.03 ml/分钟),UNaV增加约10倍(从3±0.4增至34±2.8 μeq/分钟),GFR从31±2增至49±2 ml/分钟,RPF从59±1增至120±4 ml/分钟,钠分数排泄从0.06±0.01增至0.5±0.4%(所有P<0.001)。在全身输注抑制剂时未出现这些变化,且在肾内给予阻滞剂期间的变化可通过肾内联合给予血管紧张素II而完全被阻断。肾内RAS是肾功能的一种强大生理调节因子。(摘要截短于250词)